

## VALNEVA SE

ISIN: FR0004056851

WKN: -

## Overview

2024/07/16 17:35:09

Price

3.494 EUR

Difference



4.05% (0.14)

## General attributes

ISIN FR0004056851

Symbol VLA

Exchange Euronext Paris

Currency EUR

Sector Chemical / Pharmaceutical / Health

Security type Stock

Market cap (m) 959 EUR

Benchmark CAC 40 INDEX

## Market data

Bid (Bid size) 3.47 EUR (250)

Ask (Ask size) 3.52 EUR (300)

Open 3.38 EUR

High 3.54 EUR

Low 3.35 EUR

Close (prev. day) 3.358 EUR

VWAP 3.464846 EUR

Volume (pcs) 428,109

Trading volume 1,483,332.00

Number of trades 795

Last size 133

## Futures and Options

Related Futures -

Related Options -

## PDF Downloads

Company report: VALNEVA SE



5Y



Information about previous performance does not guarantee future performance.

Source: FactSet

## Recent research

on sector		on market	
Date		Headline	Download
2024/07/12		Global Equity Ratings	
2024/06/21		Global Equity Ratings	
2024/06/14		Global Equity Ratings	
2024/05/29		Global Equity Ratings	
2024/04/26		Global Equity Ratings	

## Details

2024/07/16 17:35:09

## Price

3.494 EUR

Difference ▲ 4.05% (0.14)

## General attributes

ISIN	FR0004056851
Symbol	VLA
Exchange	Euronext Paris
Currency	EUR
Sector	Chemical / Pharmaceutical / Health
Security type	Stock
Market cap (m)	959 EUR
Benchmark	CAC 40 INDEX

## Market data

Bid (Bid size)	3.47 EUR (250)
Ask (Ask size)	3.52 EUR (300)
Open	3.38 EUR
High	3.54 EUR
Low	3.35 EUR
Close (prev. day)	3.358 EUR
VWAP	3.464846 EUR
Volume (pcs)	428,109
Trading volume	1,483,332.00
Number of trades	795
Last size	133

## Performance and Risk

	6m	1Y	3Y
Perf (%)	-17.87%	-49.58%	-68.35%
Perf (abs.)	-0.76	-3.44	-7.55
Beta	1.42	1.30	1.06
Volatility	54.99	47.59	81.79

5Y



Information about previous performance does not guarantee future performance.  
Source: FactSet

## Price data

Ø price 5 days   Ø volume 5 days (pcs.)	3.399 EUR (327,486)
Ø price 30 days   Ø volume 30 days (pcs.)	3.393 EUR (505,553)
Ø price 100 days   Ø volume 100 days (pcs.)	3.542 EUR (582,764)
Ø price 250 days   Ø volume 250 days (pcs.)	4.601 EUR (441,524)
YTD High   date	4.996 EUR (2024/01/09)
YTD Low   date	2.950 EUR (2024/03/06)
52 Weeks High   date	7.168 EUR (2023/11/10)
52 Weeks Low   date	2.950 EUR (2024/03/06)

## All listings for VALNEVA SE

Exchange <span>📍</span>	Date	Time	Price	Trading volume (mio.)	Number of trades
Xetra	2024/07/16	17:35	3.46 EUR	0.04	28
Vienna Stock Exchange	2024/07/16	15:30	3.434 EUR	0.00	4
Tradegate	2024/07/16	19:36	3.45 EUR	0.16	66
Stuttgart	2024/07/16	16:52	3.542 EUR	0.02	6
Munich	2024/	19:33	3.494 EUR	0.01	4

	07/16					
London Stock Exchange	2024/ 05/02	17:57	3.40 EUR	0.03		1
Hanover	2024/ 07/16	08:48	3.396 EUR	0.00		1
Hamburg	2024/ 07/16	08:21	3.382 EUR	0.00		1
Frankfurt	2024/ 07/16	19:13	3.484 EUR	0.02		7
FINRA other OTC Issues	2024/ 07/12	16:44	3.70 USD	0.00		1
Euronext Paris	2024/ 07/16	17:35	3.494 EUR	1.48		795
Euronext Milan MTF Trading After Hours	-	-	-	0.00		-
Duesseldorf	2024/ 07/16	20:02	3.488 EUR	0.00		6
Berlin	2024/ 07/16	08:08	3.372 EUR	0.00		1

## Company profile

### Company Logo



### Contact Details

VALNEVA SE

--

Campus Bio-Ouest, 6, rue Alain Bombard -  
44800 Saint-Herblain

Telefon: +33-2-28-07-37-10

Fax: +

E-mail: [info@valneva.com](mailto:info@valneva.com)

### PDF Downloads

Company report: VALNEVA SE



### Company Profile

Valneva SE is a specialty vaccine company, which focuses on the development, manufacturing, and commercialization of prophylactic vaccines for infectious diseases. It operates through the following segments: Commercialized Products, COVID, Vaccine Candidates, and Technologies and Services. The Commercialized Products segment markets vaccines, currently IXIARO and DUKORAL vaccines, as well as third-party products. The COVID segment develops, manufactures, and distribute related to COVID-19 vaccine candidate, VLA2001. The Vaccine Candidates segment focuses on proprietary research and development programs aiming to generate new approvable products to generate future cash flows from product sales or from commercialization through partnering with pharmaceutical companies. The Technologies and Services segment offers services and inventions at a commercialization stage. The company was founded on April 7, 1999 and is headquartered in Saint-Herblain, France.

### Members of Management Board

Thomas Lingelbach	Chairman of Managing Board
Dipal Patel	Member of Executive Committee
Franck Grimaud	Member of Executive Committee
Frederic Jacotot	Member of Executive Committee
Juan Carlos Jaramillo	Member of Executive Committee
Peter Bühler	Member of Executive Committee
Petra Pesendorfer	Member of Executive Committee
Vincent Dequenne	Member of Executive Committee

### Board of directors

Anne-Marie Graffin	Chairman of Supervisory Board
Kathrin Jansen	Member of Supervisory Board
Danièle Guyot-Caparros	Member of Supervisory Board
James Connolly	Member of Supervisory Board
James Sulat	Member of Supervisory Board
Maïlys Ferrère	Member of Supervisory Board